Biomarkers for acute myeloid leukemia
US10501802B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 30, 2014 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Dec 16, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/16
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.